Beam Therapeutics, Inc. (BEAM) stock surged 8.23% in pre-market trading on November 6, 2024, after the company reported encouraging initial clinical data from its Phase 1/2 BEACON trial evaluating BEAM-101 for the treatment of sickle cell disease.
The data showed that BEAM-101, an investigational cell therapy administered via hematopoietic stem cell transplantation, achieved robust fetal hemoglobin (HbF) induction of over 60% and reduced sickle hemoglobin (HbS) to less than 40% in patients. This hemoglobin profile mimics that of individuals with sickle cell trait, who are typically asymptomatic.
Furthermore, BEAM-101 demonstrated a favorable safety profile consistent with myeloablative conditioning and stem cell transplant. Notably, the therapy facilitated rapid neutrophil engraftment, with all patients engrafting in under 20 days, potentially leading to shorter hospital stays.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。